Diclofenac patch as an alternative to oral NSAIDs for treating minor sport injuries
Acute pain caused by musculoskeletal disorders is very common and has a significant negative impact on the quality-of-life. Various types of acute pain have been managed with different oral NSAIDs, but these are associated with an elevated risk of developing adverse events. A recently developed new diclofenac patch formulation, containing 140 mg diclofenac sodium might fulfil these criteria.
This double blind, randomized, placebo-controlled study was designed to evaluate the efficacy and safety of a topical diclofenac sodium patch (140 mg) in the relief of pain in patients with soft tissue sport injuries such as contusion, strain and sprain. Within three hours of a soft-tissue sport injury, 164 patients were recruited and randomized to receive twice a day for 7 days either a diclofenac sodium patch or control patch.
Statistically significant improvements were seen in the diclofenac group than placebo group such as reduction of pain, pain on movement and at rest, pain on pressure, time to efficacy onset and global patient and investigator efficacy assessment. This study demonstrates that diclofenac sodium patch was superior to the control patch in terms of reducing pain and improving functional outcomes and did not result in significant adverse effects.
Thus, presented study clearly shows that a newly developed diclofenac patch is very effective and safe for treating soft tissue sport injuries. Patients receiving diclofenac patch had statistically and clinically significant reductions in pain and were free of pain significantly earlier than placebo group. This allowed patients to continue their sports activities sooner thereby reducing the risk of additional injuries because pain free movement allows normal co-ordination.